Chong Kun Dang Pharmaceutical (185750) — Capital Reinvestment Ratio
Chong Kun Dang Pharmaceutical (185750) has a Capital Reinvestment Ratio of 4.85x as of September 2025, meaning it reinvests 5% of its operating cash flow (₩21.45 Billion) in capital expenditures (₩104.14 Billion). See 185750 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Chong Kun Dang Pharmaceutical Capital Reinvestment Ratio (2016–2024)
This chart tracks Chong Kun Dang Pharmaceutical's Capital Reinvestment Ratio across 9 annual periods. Check Chong Kun Dang Pharmaceutical (185750) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Chong Kun Dang Pharmaceutical (2016–2024)
Year-by-year Capital Reinvestment Ratio for Chong Kun Dang Pharmaceutical from 2016 to 2024. For live market cap and broader valuation context, see Chong Kun Dang Pharmaceutical (185750) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.03x | ₩64.29 Billion | ₩66.10 Billion | ▲ +375.4% |
| 2023 | 0.22x | ₩318.16 Billion | ₩68.81 Billion | ▼ -67.4% |
| 2022 | 0.66x | ₩67.73 Billion | ₩44.90 Billion | ▼ -82.3% |
| 2021 | 3.74x | ₩12.90 Billion | ₩48.24 Billion | ▲ +1095.0% |
| 2020 | 0.31x | ₩104.32 Billion | ₩32.64 Billion | ▲ +10.7% |
| 2019 | 0.28x | ₩77.29 Billion | ₩21.84 Billion | ▼ -45.0% |
| 2018 | 0.51x | ₩42.63 Billion | ₩21.92 Billion | ▲ +112.2% |
| 2017 | 0.24x | ₩81.67 Billion | ₩19.79 Billion | ▼ -64.5% |
| 2016 | 0.68x | ₩57.79 Billion | ₩39.44 Billion | — |